Procyon Advisors’s Integra LifeSciences IART Stock Holding History

Procyon Advisors’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-181	Closed	-$9K	–	576
2020 Q2	$9K	Buy	181 +45	+33%	+$2.21K	﹤0.01%	676
2020 Q1	$6K	Sell	136 -65	-32%	-$3.41K	﹤0.01%	679
2019 Q4	$12K	Buy	+201	New	+$12K	0.01%	602

Other funds holding IART

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Procyon Advisors's IART Position: Q3 2020 in Review

Procyon Advisors sold out of Integra LifeSciences (IART) in Q3 2020, closing a stake of 181 shares — an estimated $9K sold.

Procyon Advisors first reported a position in IART in Q4 2019 and held it in 3 quarters. The position peaked at $12K in Q4 2019. 237 funds tracked by Wall St. Rank hold IART as of Q3 2020.

Procyon Advisors reported no remaining Integra LifeSciences position as of Q3 2020 after selling out during the quarter.
Procyon Advisors sold 181 Integra LifeSciences shares in Q3 2020, an estimated $9K.
Procyon Advisors first reported a position in Integra LifeSciences in Q4 2019 and held it in 3 quarters.
Procyon Advisors's Integra LifeSciences position peaked at $12K in Q4 2019.
237 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2020.

Based on Procyon Advisors's 13F filing for Q3 2020, filed 22 Oct 2020.